A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant
Latest Information Update: 18 Nov 2018
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms SOLAR-1
- Sponsors Gilead Sciences
- 14 Apr 2018 Results assessing survival benefits of sofosbuvir-based DAA regimens in four studies (GS-US334-0125, SOLAR-1, -2 and ASTRAL-4; n=492) presented at The International Liver Congress 2018
- 10 Mar 2018 Results of integrated retrospective analysis of SOLAR-1, SOLAR-2, ASTRAL-4, and GS-US-334-0125 trials identifying predictive factors for treatment benefits and adverse events published in the Gastroenterology
- 24 Oct 2017 Results of pooled analysis of SOLAR-1, SOLAR-2, ASTRAL-4 and GS-US-334-0125 trials assessing predictive features of clinical improvement or deterioration presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases